Combination fixed-dose β agonist and steroid inhaler as required for adults or children with mild asthma: a Cochrane systematic review
Iain Crossingham(East Lancashire Hospitals NHS Trust), Timothy Hinks(University of Oxford), Rebekah Richardson(East Lancashire Hospitals NHS Trust), Philip Webb(East Lancashire Hospitals NHS Trust), Anastasia Fries(Nuffield Orthopaedic Centre), Emily O'Boyle(University of Oxford), Farhat Yasmin(Kettering General Hospital), Matthew Gowell(New College), Sally Turner(Royal Blackburn Teaching Hospital), Sanjay Ramakrishnan(Oxford BioMedica (United Kingdom))
Cited by 30
Related Papers
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial
|The Lancet Respiratory Medicine|2021|434
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
|The Lancet|2021|310
Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide
|Thorax|2021|169
Survival analysis of patients on maintenance hemodialysis
|Indian Journal of Nephrology|2014|100
Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial
|The Lancet Respiratory Medicine|2024|98